control rate, and fewer adverse effects than component monotherapies. The SELECT (Systolic Evaluation of Lotrel® Efficacy and Comparative Therapies) trial was a randomized, multicenter, prospective, doubleblinded, parallel-group study that compared the effects of amlodipine/ benazepril combination therapy with those of amlodipine and benazepril monotherapies on SBP in patients Ն55 years of age with systolic hypertension (mean seated SBP 160-200 mm Hg; mean daytime ambulatory SBP 150-200 mm Hg). Eligible patients had newly diagnosed hypertension or had discontinued previous antihypertensive medication. Following a single-blind, 2-4-week, placebo run-in period, patients were randomized to: amlodipine/benazepril 5/20 mg qd, amlodipine 5 mg qd, or benazepril 20 mg qd. Patients were maintained on this treatment for a period of 8 weeks. The primary objective of the study was to compare the effects of combination therapy with those of component monotherapy on mean 24-hour SBP. Secondary objectives were to assess the effects of these therapies on mean 24-hour pulse pressure, 24-hour diastolic BP, incidence of peripheral edema, safety, quality of life, and response and control rates. Primary results will be available for presentation. Monotherapy controls arterial blood pressure (BP) in only about half of hypertensive patients, and may result in adverse effects which further diminishes efficacy through non-compliance. Combination drug therapy can offer better BP reduction while minimizing adverse effects by using lower doses of 2 drugs instead of higher doses of 1 drug. The SOLACE (Study Comparing the Efficacy of Lotrel® vs Amlodipine in the Treatment of Moderate to Severe Hypertension) trial was a 12-week, randomized, multicenter, double-blind, parallel-group study. The primary objective of the trial was to compare the percentage of subjects treated with fixed-dose combination amlodipine/benazepril therapy with subjects treated with amlodipine monotherapy who achieved first treatment success in systolic BP (SBP), defined as a reduction in SBP of Ն25 mm Hg (if baseline SBP was Ͻ180 mm Hg); or a reduction in SBP of Ն32 mm Hg (if baseline systolic BP was 180 mm Hg). Patients 18 to 80 years of age (inclusive) with a documented diagnosis of stage 2 or stage 3 essential hypertension (SBP of Ն160 mm Hg and Յ210 mm Hg and/or a diastolic BP [DBP] Ն100 mm Hg and Յ120 mm Hg) were eligible for the trial. Subjects taking antihypertensive medication at screening or within 2 weeks prior to screening underwent a minimum 72-h washout from their current medication. At the 72-h safety visit, subjects with an SBP of Ͻ200 mm Hg and/or a DBP of Ͻ110 mm Hg continued the washout period for 1 week. Following the 3-to 10-day placebo washout period, 317 patients were randomized to either amlodipine/benazepril 5/20 mg qd or amlodipine 5 mg qd (dose level 1). Patients who achieved a target BP of Յ130/85 mm Hg at Week 2 continued treatment at dose level 1; those who did not achieve target BP were titrated to amlodipine/ benazepril 10/20 mg qd or amlodipine 10 mg qd (dose level 2). If a patient's SBP was Ն180 mm Hg and Յ210 mm Hg and/or DBP was Ն110 mm Hg and Յ120 mm Hg after 3 weeks on dose level 2, hydrochlorothiazide (HCTZ) 12.5 mg qd was added. Patients with an SBP Ͼ210 mm Hg and/or a DBP Ͼ120 mm Hg at any time during the trial were discontinued from the study. Primary results of SOLACE will be available for presentation.
P-438 COMPARISON OF THE EFFECTS OF AMLODIPINE/ BENAZEPRIL FIXED-DOSE COMBINATION THERAPY VS AMLODIPINE MONOTHERAPY ON SYSTOLIC AND DIASTOLIC BLOOD PRESSURE IN STAGE 2 OR STAGE 3 HYPERTENSION: RESULTS OF THE SOLACE TRIAL
Monotherapy controls arterial blood pressure (BP) in only about half of hypertensive patients, and may result in adverse effects which further diminishes efficacy through non-compliance. Combination drug therapy can offer better BP reduction while minimizing adverse effects by using lower doses of 2 drugs instead of higher doses of 1 drug. The SOLACE (Study Comparing the Efficacy of Lotrel® vs Amlodipine in the Treatment of Moderate to Severe Hypertension) trial was a 12-week, randomized, multicenter, double-blind, parallel-group study. The primary objective of the trial was to compare the percentage of subjects treated with fixed-dose combination amlodipine/benazepril therapy with subjects treated with amlodipine monotherapy who achieved first treatment success in systolic BP (SBP), defined as a reduction in SBP of Ն25 mm Hg (if baseline SBP was Ͻ180 mm Hg); or a reduction in SBP of Ն32 mm Hg (if baseline systolic BP was 180 mm Hg). Patients 18 to 80 years of age (inclusive) with a documented diagnosis of stage 2 or stage 3 essential hypertension (SBP of Ն160 mm Hg and Յ210 mm Hg and/or a diastolic BP [DBP] Ն100 mm Hg and Յ120 mm Hg) were eligible for the trial. Subjects taking antihypertensive medication at screening or within 2 weeks prior to screening underwent a minimum 72-h washout from their current medication. At the 72-h safety visit, subjects with an SBP of Ͻ200 mm Hg and/or a DBP of Ͻ110 mm Hg continued the washout period for 1 week. Following the 3-to 10-day placebo washout period, 317 patients were randomized to either amlodipine/benazepril 5/20 mg qd or amlodipine 5 mg qd (dose level 1). Patients who achieved a target BP of Յ130/85 mm Hg at Week 2 continued treatment at dose level 1; those who did not achieve target BP were titrated to amlodipine/ benazepril 10/20 mg qd or amlodipine 10 mg qd (dose level 2). If a patient's SBP was Ն180 mm Hg and Յ210 mm Hg and/or DBP was Ն110 mm Hg and Յ120 mm Hg after 3 weeks on dose level 2, hydrochlorothiazide (HCTZ) 12.5 mg qd was added. Patients with an SBP Ͼ210 mm Hg and/or a DBP Ͼ120 mm Hg at any time during the trial were discontinued from the study. Primary results of SOLACE will be available for presentation. The objective of the present study was to compare the antihypertensive effects of amlodipine (AML), ramipril (RAM) and telmisartan (TEL) on 24-hour ambulatory blood pressure (BP) in patients with mild to moderate essential hypertension. For this purpose, 57 patients (41 M/16F) with a mean age of 60.1Ϯ7.0 years were enrolled in the study and were randomised to either RAM 2.5 mg (nϭ17), AML 5 mg (nϭ22) or TEL 80 mg (nϭ18) for a period of 8 weeks. Patients were respectively titrated to RAM 5 mg and 10 mg after 1 and 4 weeks of treatment and to AML 10 mg at week 4. Patients treated with TEL received 80 mg during the 8 weeks of the study. Ambulatory BP monitoring was performed at baseline and at the end of the 8-week treatment period.
At the end of the study, TEL and AML provided significant (pϽ0.05) and similar reductions in ambulatory BP during the daytime (6h00-23h00) and the nighttime (23h00-06h00) periods with a trend in favour of AML. In contrast, although RAM provided significant reductions in ambulatory systolic and diastolic BP from 2 to 6 hours post dose (peak effect), it failed to induce significant reductions in mean daytime and nighttime ambulatory BP. In addition, comparisons of the area-underthe-curve (AUC) for the mean BP reductions during the 24-hour interval demonstrated significant and similar antihypertensive effects on systolic, diastolic and mean BP for TEL and AML. In contrast, the 24-hour ambulatory AUCs were not significantly modified by RAM.
The results of the present study confirm the efficacy of both TEL and AML in reducing ambulatory BP during each period of the 24-hour interval. Because BP reduction with RAM was restricted to its peak effect, our data do not support the use of this agent as administered once daily. 
